Inhibiting PARP as a Strategic Target in Cancer
Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2016 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (97 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546728204498 |
---|---|
ctrlnum |
(CKB)3800000000216181 (oapen)https://directory.doabooks.org/handle/20.500.12854/50258 (EXLCZ)993800000000216181 |
collection |
bib_alma |
record_format |
marc |
spelling |
Kristin Zorn auth Inhibiting PARP as a Strategic Target in Cancer Frontiers Media SA 2016 1 electronic resource (97 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage. English DNA reapir PARP inhibitor Homologous Recombination combination therapy DNA Damage Cancer 2-88919-955-X Christina Annunziata auth |
language |
English |
format |
eBook |
author |
Kristin Zorn |
spellingShingle |
Kristin Zorn Inhibiting PARP as a Strategic Target in Cancer Frontiers Research Topics |
author_facet |
Kristin Zorn Christina Annunziata |
author_variant |
k z kz |
author2 |
Christina Annunziata |
author2_variant |
c a ca |
author_sort |
Kristin Zorn |
title |
Inhibiting PARP as a Strategic Target in Cancer |
title_full |
Inhibiting PARP as a Strategic Target in Cancer |
title_fullStr |
Inhibiting PARP as a Strategic Target in Cancer |
title_full_unstemmed |
Inhibiting PARP as a Strategic Target in Cancer |
title_auth |
Inhibiting PARP as a Strategic Target in Cancer |
title_new |
Inhibiting PARP as a Strategic Target in Cancer |
title_sort |
inhibiting parp as a strategic target in cancer |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2016 |
physical |
1 electronic resource (97 p.) |
isbn |
2-88919-955-X |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT kristinzorn inhibitingparpasastrategictargetincancer AT christinaannunziata inhibitingparpasastrategictargetincancer |
status_str |
n |
ids_txt_mv |
(CKB)3800000000216181 (oapen)https://directory.doabooks.org/handle/20.500.12854/50258 (EXLCZ)993800000000216181 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Inhibiting PARP as a Strategic Target in Cancer |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787548668785590275 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02213nam-a2200349z--4500</leader><controlfield tag="001">993546728204498</controlfield><controlfield tag="005">20231214133704.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2016 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3800000000216181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/50258</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993800000000216181</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kristin Zorn</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhibiting PARP as a Strategic Target in Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (97 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA reapir</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PARP inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Homologous Recombination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combination therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA Damage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-955-X</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christina Annunziata</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 06:02:42 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2017-09-30 19:47:25 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338371040004498&Force_direct=true</subfield><subfield code="Z">5338371040004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338371040004498</subfield></datafield></record></collection> |